MENU

Peptide Therapeutics and GLP-1 Explained | Drug Discovery & DDS

Back to Technology, Institution & Company Guides

TECHNOLOGY EXPLAINER

Peptide Drugs and GLP-1
— a molecule that vanishes in two minutes, made to last a week with a single fatty acid

Native GLP-1 (glucagon-like peptide-1) is broken down in the blood in 1.5 to 2 minutes. Turning it into a once-weekly drug took a single amino-acid substitution and a chemical modification that attaches one fatty acid. Making it oral called for another material, an absorption enhancer, and there are two routes to manufacture: yeast fermentation and solid-phase synthesis.

Built on primary sources: FDA-approved prescribing information (DailyMed), European Public Assessment Reports (EPAR) of the European Medicines Agency (EMA), FDA publications, the U.S. Code of Federal Regulations, Nobel Foundation announcements, official company announcements and peer-reviewed papers (Frontiers in Endocrinology, J Med Chem, Sci Transl Med, PNAS, J Org Chem) / Last updated September 2026

Explanatory image generated with ImageGen that concretely shows the action of GLP-1 receptor agonistsAI-generated concept
Explanatory image generated with ImageGen. A conceptual image of the action of GLP-1 receptor agonists. It does not show real equipment, products or micrographs, nor accurate molecular shapes, dimensions or measured data.
What this article covers
  1. Peptide drugs and GLP-1 (the short version)
  2. Receptors and agonists — the "lock" and the "duplicate key"
  3. Why it disappears in two minutes, and two countermeasures
  4. Attaching a fatty acid — a design that "hitches a ride" on albumin
  5. Our calculation: how many thousand times the half-life was extended
  6. A materials engineer's view 1: the fatty acid and the PEG-like linker are "interface design"
  7. Going oral — the absorption enhancer SNAC and what happens in the stomach
  8. Our calculation: how much more drug substance does a pill need?
  9. How it is made — yeast fermentation plus chemical modification, or solid-phase synthesis
  10. A materials engineer's view 2: in solid-phase synthesis, the yield of every step compounds
  11. Small-molecule GLP-1 receptor agonists
  12. Generics and regulatory moves / Open issues, and what is not yet settled
  13. Glossary / References / Claim-to-source audit
How claims are labelled in this article

Sourced = stated in published material (link given)
Our calculation = a figure this article derived from stated assumptions
Not yet confirmed = a plan or target whose results have not been confirmed
Structural arrangements and readings on materials and process design are marked separately as commentary.

Medical disclaimer

This article explains the molecular design, formulation and manufacture of peptides from the viewpoint of materials technology. It does not deal with efficacy or safety, such as weight loss or improvement of blood glucose, and it does not compare products. It is not medical advice. The doses and administration conditions in the prescribing information are quoted as figures for explaining the amount of drug substance and the mechanism of absorption, not as instructions for use. For the use of GLP-1 receptor agonists, please always consult a medical professional.

1. Peptide drugs and GLP-1 (the short version)

  • What a peptide drug is: a drug made of a molecule in which a few to a few dozen amino acids are linked. U.S. regulation defines a protein as a polymer of more than 40 amino acidsSourced, and the FDA treats polymers of 40 or fewer amino acids as "peptides"Sourced
  • What GLP-1 is: a hormone released from the gut in response to food. The VICTOZA prescribing information states that native GLP-1(7-37) has a half-life of 1.5 to 2 minutes because it is degraded by enzymes found throughout the body, namely DPP-4 (dipeptidyl peptidase-4) and neutral endopeptidase (NEP)Sourced
  • What is at the heart of the technology: it is the history of solving, one by one, the three weaknesses of peptides ("broken down quickly", "cleared quickly by the kidney" and "not absorbed when swallowed") through chemical and materials design: amino-acid substitution, fatty-acid modification and an absorption enhancer (this article's arrangement)
The single most important line in this article

What supports the once-weekly dosing of semaglutide is "a single fatty acid" in the molecule. The prescribing information states that the main prolonging mechanism of semaglutide is albumin binding, promoted by modifying the lysine at position 26 with a hydrophilic spacer and a C18 fatty diacidSourced. The peptide reversibly "hitches a ride" on a protein (albumin) that is abundant in blood. This is molecular design, and it is also interface and adsorption design (commentary in this article).

2. Receptors and agonists — the "lock" and the "duplicate key"

A receptor is a protein, on the cell surface for example, that passes a signal into the cell when a particular molecule binds to it. An agonist is a molecule that binds to a receptor and makes it work in the same way as the natural substance.

  • The OZEMPIC prescribing information describes semaglutide as a GLP-1 analog with 94% sequence homology to human GLP-1 that selectively binds to and activates the GLP-1 receptor, the target of native GLP-1Sourced
  • The MOUNJARO prescribing information describes tirzepatide as a once-weekly GIP (glucose-dependent insulinotropic polypeptide) receptor and GLP-1 receptor agonist. It is a design that acts on two receptorsSourced
  • Kawai et al. treat the GLP-1 receptor as one of the class B G protein-coupled receptors (GPCRs) and report the small-molecule agonist LY3502970 as a partial agonistSourced. A partial agonist is one that makes the receptor work to a lesser degree than the natural substance (commentary in this article)

3. Why it disappears in two minutes, and two countermeasures

Native GLP-1 is short-lived because two things overlap: it is cut by enzymes, and it is small, so the kidney clears it quickly. The review by Knudsen and Lau explains that the aim of fatty-acid modification is to make analogs that bind reversibly to albumin, and thereby protect the peptide from both DPP-IV degradation and renal filtrationSourced.

(1) Countering the enzyme — replace one amino acid

According to the same review, when the whole GLP-1 sequence was examined by replacing residues one at a time with alanine, only the introduction of aminoisobutyric acid (Aib) at position 8 combined stability against DPP-IV with high affinity for the receptorSourced. The OZEMPIC prescribing information likewise states that semaglutide is modified at position 8 to stabilize it against DPP-4 degradationSourced. Aib is a non-coded amino acid that is not used in natural proteins. Tirzepatide also contains Aib at positions 2 and 13Sourced.

(2) Countering renal clearance and degradation — hitch a ride on a large protein

Another way is to make the peptide itself larger. The same review lists fusion to albumin itself (albiglutide) and fusion to the Fc region of IgG (dulaglutide) as other ways to reduce renal clearanceSourced. Novo Nordisk's approach, by contrast, was not to enlarge the peptide by covalent bonding but to bind it reversibly to albumin through a fatty acidSourced.

Where native GLP-1 and its analogues were changed (concept) Band = peptide chain (N-terminus at left) / circle = substituted or modified position / wavy line = fatty-acid side chain Native GLP-1 31 residues (positions 7-37) position 8 (cleaved by DPP-4) 1.5-2 min liraglutide 97% homology position 34: Lys→Arg position 26: γGlu + C16 13 hours semaglutide 94% homology position 8: Aib position 34: Arg position 26: hydrophilic spacer + C18 diacid about 1 week tirzepatide: 39 residues based on the GIP sequence; Aib at positions 2 and 13, C20 diacid on lysine 20 * Positions, modifications and half-lives: FDA labels [Refs. 1, 4, 5]. Why Aib was chosen: Knudsen and Lau (2019) [Ref. 7]. * Band length, circle positions and the wavy line are schematic and do not show real 3D structure or side-chain length.
Fig. 1. Concept diagram (vector drawing). The substitution positions, fatty-acid modifications and half-lives of each molecule come from the OZEMPIC, VICTOZA and MOUNJARO prescribing information [Refs. 1, 4, 5], and how Aib came to be introduced from Knudsen and Lau (2019) [Ref. 7]. The bands, circles and wavy lines are schematic markers of position and do not show chemical structures or 3D structure. The times at the right edge are the half-lives given in each label; the value for native GLP-1 is from the VICTOZA label.

4. Attaching a fatty acid — a design that "hitches a ride" on albumin

MoleculeBackboneWhere the fatty acid is attachedSpacer (linker)Fatty acidHalf-life (label)
liraglutideGLP-1, 97% homology (Lys→Arg at position 34)Lysine at position 26Glutamic acidC16 fatty acid (palmitic acid)13 hours
semaglutideGLP-1, 94% homology (Aib at position 8, Arg at position 34)Lysine at position 26Hydrophilic spacerC18 fatty diacidAbout 1 week
tirzepatideBased on the GIP sequence, 39 residues (Aib at positions 2 and 13, C-terminal amide)Lysine at position 20γ-Glu + 2 × 8-amino-3,6-dioxaoctanoic acid1,20-eicosanedioic acid (C20)About 5 days

All Sourced (the VICTOZA, OZEMPIC and MOUNJARO prescribing information [Refs. 4, 1, 5]; the linker composition of tirzepatide from the EMA public assessment report [Ref. 6]). For the spacer of semaglutide, Knudsen and Lau describe a γGlu-2xOEG linker [Ref. 7].

The choice of fatty-acid length and of how to attach it to the peptide was settled by systematic exploration.

  • Comparing C12 to C20: Knudsen and Lau state that, after systematic testing of fatty-acid derivatives from C12 to C20, the combination of a C18 fatty diacid and a γGlu-2xOEG linker gave the best balance of high albumin affinity and strong action at the GLP-1 receptorSourced
  • Attach only one: the same review says that attaching two fatty acids reduced action at the receptorSourced. The OZEMPIC prescribing information also states that the substitution at position 34 is there so that only one fatty diacid is attachedSourced
  • On the albumin side: the review notes that crystal-structure analysis has shown fatty acids of C10 to C18 binding at seven sites on albumin, and explains that albumin has a large capacity to carry fatty acids thanks to its high blood concentration, its multiple binding sites and its long half-lifeSourced
  • The price: the abstract of the 2015 paper by Lau et al. reports that the GLP-1 receptor affinity of semaglutide (0.38 ± 0.06 nM) fell to one third of that of liraglutide, while its albumin affinity roseSourced. It can be read as a design that chose "staying long" over "acting strongly" (commentary in this article)

5. Our calculation: how many thousand times the half-life was extended

Our calculation: ratios to native GLP-1

We convert the half-lives in the prescribing information to minutes and compare themOur calculation.

  • Native GLP-1: 1.5 to 2 minutes (as stated in the VICTOZA label)
  • liraglutide: 13 hours = 780 minutes → 780 ÷ 2 to 780 ÷ 1.5 = about 390 to 520 times
  • tirzepatide: about 5 days = 7,200 minutes → about 3,600 to 4,800 times (a ratio to GLP-1, not to native GIP)
  • semaglutide: about 1 week = 10,080 minutes → 10,080 ÷ 2 to 10,080 ÷ 1.5 = about 5,000 to 6,700 times

Assumptions and limits: the value for native GLP-1 was obtained under conditions such as intravenous administration, whereas the analog values are after subcutaneous administration, so the measurement conditions are not matched. "About 1 week" and "about 5 days" are the rounded figures in the labels. This conversion is for showing differences in orders of magnitude and does not rank the drugs as medicines.

Half-lives from the labels on a logarithmic scale (our calculation) The horizontal axis is the common logarithm of time in minutes; each gridline step is a factor of 10 native GLP-1 1.5-2 min liraglutide 13 hours (about 450 times) tirzepatide about 5 days semaglutide about 1 week 1 min 10 min 100 min 1,000 min 10,000 min From native GLP-1 to semaglutide, half-life grew by about 3.7 orders of magnitude (about 5,000 to 6,700 times) * Half-lives are the values in the VICTOZA, MOUNJARO and OZEMPIC labels [Refs. 4, 5, 1]. Ratios and bar lengths are our calculation. * Measurement conditions (such as route) are not matched. This compares orders of magnitude and does not rank the drugs.
Fig. 2. Drawing that includes our calculation (vector drawing). The half-lives are the values in the VICTOZA (native GLP-1 and liraglutide), MOUNJARO and OZEMPIC prescribing information [Refs. 4, 5, 1]. The log-converted bar lengths and the ratios (about 450 times, near the middle of 390 to 520, and about 5,000 to 6,700 times) are values this article calculated, not published values. The bar for native GLP-1 is drawn at 2 minutes.

6. A materials engineer's view 1: the fatty acid and the PEG-like linker are "interface design"

What a materials engineer should notice: where, how many and how long an amphiphilic "tail" should be

Seen with a materials eye, the side chains of semaglutide and tirzepatide have a structure much like the design of a surfactant or a coupling agent (commentary in this article).

  • The hydrophobic tail: a C16, C18 or C20 fatty (di)acid. It was chosen by exploring the length systematicallySourced
  • The hydrophilic connector: the linker of tirzepatide consists of γ-Glu and two 8-amino-3,6-dioxaoctanoic acid units, which the EMA report describes as a linker partly resembling polyethylene glycolSourced. It reads as a hydrophilic spacer containing ethylene oxide units whose role is to hold the fatty acid away from the peptide (commentary in this article)
  • Controlling the number: attaching two reduces action at the receptorSourced. That is why the lysine at position 34 is replaced with arginine, leaving a single reactive siteSourced

The last point is suggestive for a materials person. By removing from the sequence in the first place the functional group that you do not want to react, the later chemical modification can be made to occur regioselectively at one site only. This is the same idea as blocking the other reactive sites beforehand when you want to introduce a surface-treatment agent at just one point on a polyfunctional substrate (commentary in this article).

Also, "adsorption to albumin" is meaningless unless it is reversible. If it binds too strongly the drug cannot reach the receptor; if too weakly it leaves through the kidney. The trade that Lau et al. showed, a drop of the receptor affinity to one third in exchange for higher albumin affinitySourced, can be read as a design problem of carriers and adsorbents: where to set the balance between adsorption and desorption (commentary in this article).

7. Going oral — the absorption enhancer SNAC and what happens in the stomach

Making a peptide into a pill was long a hard problem. The abstract of the 2018 paper by Buckley et al. opens by saying that oral administration of therapeutic peptides is hampered by poor absorption across the gastrointestinal barrier and by extensive degradation by proteolytic enzymesSourced.

What the paper says: where and how is a semaglutide tablet absorbed?
  • For semaglutide tableted with the absorption enhancer SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate), absorption takes place in the stomach, in contrast to the intestinal absorption usual for small molecules; it is confined to a very small area next to the tablet surface and requires co-formulation with SNACSourced
  • SNAC protects against enzymatic degradation through a local buffering effect and raises absorption only temporarilySourced
  • The mechanism of absorption is compound-specific and transcellular, and there is no evidence of an effect on tight junctionsSourced
Explanatory image generated with ImageGen that concretely shows the action of GLP-1 receptor agonists (Fig. 3)
Fig. 3. Explanatory image generated with ImageGen. A conceptual image of the action of GLP-1 receptor agonists. It does not show real equipment, products or micrographs, nor accurate molecular shapes, dimensions or measured data. The original schematic, with numbers and sources, can be viewed below.
Show the original schematic with sources and numbers
Oral semaglutide is absorbed through the stomach wall right next to the tablet (concept) Brown = tablet and the local zone formed as it dissolves / blue = gastric epithelial cells / green = bloodstream side In the stomach Tablet SNAC buffers the local zone and protects against enzymes Elsewhere in the gastric juice, enzymes keep breaking it down Passes through the cells (transcellular) Into the bloodstream. Estimated absolute bioavailability about 0.4-1% (RYBELSUS), about 1-2% (newer tablet) * Absorption site, local buffering and transcellular route: Buckley et al. (2018) [Ref. 9]; bioavailability: labels [Refs. 2, 3]. * The figure is a schematic of the idea and does not show tablet size, zone extent or cell shape.

Original schematic for Fig. 3 (concept diagram, vector drawing). That absorption takes place in the stomach next to the tablet surface, the local buffering action of SNAC, and the absence of evidence for an effect on tight junctions in the transcellular route come from Buckley et al. (2018) [Ref. 9]; the estimated absolute bioavailability comes from the prescribing information of oral semaglutide [Refs. 2, 3]. The shape and size of the zone and the arrangement of the cells are schematic and do not show real anatomy.

"Materials design of the formulation" as read from the prescribing information

FormulationSemaglutide contentExcipients (label)Estimated absolute bioavailability
OZEMPIC (injection)—Disodium phosphate dihydrate, propylene glycol, phenol and others89% (subcutaneous)
RYBELSUS tablets3, 7, 14 mgMagnesium stearate, microcrystalline cellulose, povidone, SNACAbout 0.4–1%
OZEMPIC tablets1.5, 4, 9 mgMagnesium stearate and SNAC onlyAbout 1–2%
WEGOVY tabletsMaintenance dose 25 mgContains SNAC as the absorption enhancerAbout 1–2%

All Sourced (the OZEMPIC injection, oral semaglutide tablet and WEGOVY prescribing information [Refs. 1, 2, 3]). The label of the oral semaglutide tablets describes absorption occurring mainly in the stomach and the results of clinical pharmacology studies in which absorption changed with the amount of water at dosing and the fasting time after dosingSourced.

Same drug substance, tablets with different excipients

The label of the oral semaglutide tablets states that no clinically meaningful difference in steady-state AUC (area under the concentration–time curve) and Cmax (peak concentration) was seen between RYBELSUS 3, 7 and 14 mg and OZEMPIC tablets 1.5, 4 and 9 mg, and at the same time that they cannot be interchanged on a milligram basisSourced. If exposure is comparable between 14 mg and 9 mg, the calculation gives about 36% less drug substance (1 − 9 ÷ 14)Our calculation. The formulation difference we can confirm from the labels is the presence or absence of microcrystalline cellulose and povidoneSourced. However, whether the difference in content arose from this formulation change alone could not be confirmed in the material we consulted.

8. Our calculation: how much more drug substance does a pill need?

Our calculation: weekly drug-substance amount of the injection and the tablet under the same product name

The WEGOVY prescribing information gives a maintenance dose of 2.4 mg once weekly for the injection and 25 mg once daily for the tabletSourced. We put both on a weekly drug-substance basisOur calculation.

  • Injection: 2.4 mg/week
  • Tablet: 25 mg × 7 days = 175 mg/week
  • Ratio: 175 ÷ 2.4 = about 73 times
  • By the amount absorbed: injection 2.4 × 0.89 = about 2.1 mg; tablet 175 × 0.01–0.02 = about 1.8–3.5 mg. The amounts entering the body are of the same order

Assumptions and limits: the bioavailabilities are the estimates in the labels (injection 89%, tablet about 1–2%) multiplied as they stand. Actual exposure varies between individuals, and the label itself notes large variability in blood concentration for the tabletSourced. This does not show therapeutic equivalence. It is a conversion to show the order of magnitude of the drug substance needed.

Weekly semaglutide drug-substance amount: injection and tablet (our calculation) Converted from the maintenance doses in the WEGOVY label. Bar length is proportional to mass Injection (weekly) 2.4 mg Tablet (daily) 175 mg (25 mg × 7 days) Ratio of amounts given about 73 times 175 ÷ 2.4 Amount absorbed (dose × BA) about 2.1 mg and 1.8-3.5 mg 2.4×0.89 / 175×0.01-0.02 * Doses and bioavailability (injection 89%, tablet about 1-2%) are the values in the WEGOVY label [Ref. 3]. * 175 mg, about 73 times and the absorbed amounts are our calculation, not published values. Not a claim of therapeutic equivalence.
Fig. 4. Drawing that includes our calculation (vector drawing). The doses and estimated absolute bioavailability are the values in the WEGOVY prescribing information [Ref. 3]. The weekly drug-substance amounts, the ratio of about 73 times and the absorbed amounts are values this article calculated, not published values. Individual variation and variability in blood concentration are not taken into account, and the figure does not show therapeutic equivalence.
What a materials engineer should notice: going oral also means "making about 70 times more drug substance"

The calculation in this chapter shows the essence of oral peptides. With an absorption of 1–2%, the amount to be swallowed has to be several tens of times, close to a hundred times, that of the injection. Going oral is a formulation device, and at the same time a decision that raises the production volume of drug substance by more than an order of magnitude (commentary in this article).

Moreover, the active ingredient per tablet is a few mg to 25 mg, and the rest is excipients such as SNAC. As Buckley et al. showed, absorption takes place in the immediate vicinity of the tablet surfaceSourced, so how the tablet disintegrates and dissolves in the stomach, that is, the design of disintegration and dissolution, can be expected to govern absorption directly (commentary in this article). That the label instructs not to split, crush or chew the tabletSourced also shows that the shape of the tablet itself is part of its function.

The absorption enhancer is not a "material that does nothing" but a functional excipient. Knudsen and Lau note that SNAC has Generally Recognized As Safe (GRAS) status in the United States for food use, while also writing that the molecular mechanism of its absorption enhancement is not fully understood (as of 2019)Sourced.

9. How it is made — yeast fermentation plus chemical modification, or solid-phase synthesis

Even for peptides of the same GLP-1 family, manufacture divides into two routes.

MoleculeManufacturing method (as stated in published material)Source
liraglutideThe precursor peptide is made by a process that includes recombinant DNA expression in baker's yeast (Saccharomyces cerevisiae), and a C16 fatty acid is attached through a glutamic-acid spacer to lysine at position 26VICTOZA prescribing information
semaglutideThe peptide backbone is made by yeast fermentationOZEMPIC prescribing information
tirzepatideSynthesized by standard solid-phase peptide synthesis (SPPS), including the addition of the side chain on lysine 20. Cleavage from the resin removes the side-chain protecting groups at the same time; the product is purified by reversed-phase chromatography, then concentrated, solvent-exchanged, isolated and dried to give the drug substance. The drug substance is made at one manufacturing siteEMA public assessment report

All Sourced (the VICTOZA and OZEMPIC prescribing information [Refs. 4, 1]; the EMA public assessment report for Mounjaro [Ref. 6]).

Knudsen and Lau give, as an additional advantage of replacing lysine 34 with arginine in the design of liraglutide, that it made the analog suitable for a semi-recombinant process, in which the peptide backbone is made recombinantly and the fatty acid is attached afterwards by a simple chemical reactionSourced. The molecular design was already deciding the manufacturing method (commentary in this article). On the other hand, a non-coded amino acid such as Aib cannot be made by cells as it is. At which step the Aib at position 8 of semaglutide is introduced could not be confirmed in the material we consulted.

Explanatory image generated with ImageGen that concretely shows the action of GLP-1 receptor agonists (Fig. 5)
Fig. 5. Explanatory image generated with ImageGen. A conceptual image of the action of GLP-1 receptor agonists. It does not show real equipment, products or micrographs, nor accurate molecular shapes, dimensions or measured data. The original schematic, with numbers and sources, can be viewed below.
Show the original schematic with sources and numbers
Two manufacturing routes for GLP-1-class peptides (concept) Top = semi-recombinant process (liraglutide, semaglutide) / bottom = solid-phase peptide synthesis (tirzepatide) Semi-recombinant process 1. Express in yeast Recombinant DNA makes the peptide backbone 2. Recover the backbone The reactive site is one lysine at position 26 3. Chemical modification Attach the spacer and the fatty acid Drug substance Biology plus chemistry Solid-phase peptide synthesis (SPPS) 1. Extend on the resin One residue at a time; washing removes by-products 2. Cleavage Cut from the resin and deprotect at the same time 3. Reversed-phase Chromatography purifies the crude drug substance Drug substance Concentrate, isolate, dry * Top: labels [Refs. 4, 1] and Knudsen and Lau (2019) [Ref. 7]. Bottom: EMA report [Ref. 6] and Nobel Foundation [Ref. 10]. * Dividing the process into three steps is this article's arrangement and does not show every actual step or control item.

Original schematic for Fig. 5 (concept diagram, vector drawing). The semi-recombinant process comes from the VICTOZA and OZEMPIC prescribing information [Refs. 4, 1] and Knudsen and Lau (2019) [Ref. 7]; the steps of solid-phase peptide synthesis from the EMA public assessment report for Mounjaro [Ref. 6]; and the principle of removing by-products by washing from the Nobel Foundation's 1984 Chemistry announcement [Ref. 10]. The division into three steps is this article's arrangement and does not show the actual steps, equipment or conditions of any company.

10. A materials engineer's view 2: in solid-phase synthesis, the yield of every step compounds

The figures given in the Nobel Foundation announcement (Chemistry, 1984)

The announcement of the 1984 Nobel Prize in Chemistry explains that, in conventional solution synthesis, even a 90% yield at each synthetic step, which is a very good yield, leaves an overall yield of 0.003% after 100 stepsSourced. With solid-phase synthesis, the yield of each step can be raised to 99.5% or more, and in the same example the overall yield rises from 0.003% to 61%Sourced.

Our calculation: how the coupling rate of each step works out for a 39-residue peptide

Tirzepatide has 39 residuesSourced. After the first residue is attached to the resin, we assume 38 couplings are needed (a simplification that does not count side-chain additions or deprotections)Our calculation.

  • 99.9% per step → 0.99938 = about 96%
  • 99.5% per step → 0.99538 = about 83%
  • 99% per step → 0.9938 = about 68%
  • 98% per step → 0.9838 = about 46%
  • 90% per step → 0.9038 = about 1.8%

Turned around, even at 99% per step, about 32% of the chains have a coupling missing at some step. Assumptions and limits: actual process conditions and yields are not published, and these numbers are a simple calculation applying assumed coupling rates. Whether a chain with a missed coupling keeps growing or is stopped partway, and so the actual distribution of by-products, varies with the process.

Share of full-length chains left after 38 couplings (our calculation) Values multiply an assumed coupling rate per step. Bar length is proportional to the share (full width = 100%) 99.9% per step about 96% 99.5% per step about 83% 99% per step about 68% 98% per step about 46% 90% per step about 1.8% A 1% difference per step becomes the difference between 68% and 83% at 38 steps * 39 residues: EMA report for tirzepatide [Ref. 6]; yields compounding with step number: Nobel Foundation [Ref. 10]. * Per-step coupling rates are assumptions of this article, not actual manufacturing conditions or yields. Shares are our calculation.
Fig. 6. Drawing that includes our calculation (vector drawing). The figure of 39 residues comes from the EMA public assessment report for Mounjaro [Ref. 6], and the compounding of yield with the number of steps from the Nobel Foundation's 1984 Chemistry announcement [Ref. 10]. The per-step coupling rates are assumptions made by this article and the shares are values it calculated; they do not show actual manufacturing conditions or yields.
What a materials engineer should notice: the impurity is "almost the product"

The difficulty of solid-phase synthesis lies less in the yield itself than in the nature of the impurities. A chain with one coupling missing has almost the same size and the same composition as the target molecule. Purification therefore needs a separation that can tell a one-residue difference apart (reversed-phase chromatography in the EMA report)Sourced. Because the chain is built by sequential reactions, this is the same kind of problem as polymer synthesis, which deals with distributions of degree of polymerization and end-group defects (commentary in this article).

Another is the amount of solvents and reagents. The abstract of the 2019 paper by Isidro-Llobet et al. points out that peptide synthesis today relies mainly on older technology, uses large quantities of highly hazardous reagents and solvents, and has paid little attention to green chemistry and engineering, and notes that in 2016 the ACS Green Chemistry Institute Pharmaceutical Roundtable named the development of greener processes for peptide active ingredients a critical unmet needSourced. If going oral multiplies the amount of drug substance several tens of times, as calculated in Chapter 8, then the use of solvents, resin, protected amino acids and purification media will scale by the same ratio (commentary in this article). Solid supports, protected amino acids, alternative solvents and separation media: this is an area with large room for improvement from the materials side.

Explanatory image generated with ImageGen that concretely shows the action of GLP-1 receptor agonists (Fig. 7)
Fig. 7. Explanatory image generated with ImageGen. A conceptual image of the action of GLP-1 receptor agonists. It does not show real equipment, products or micrographs, nor accurate molecular shapes, dimensions or measured data.

11. Small-molecule GLP-1 receptor agonists

Instead of making a peptide oral, there is also the approach of moving the receptor with a small molecule from the start.

  • A structural clue: in a 2020 PNAS paper on the small-molecule agonist LY3502970 (OWL833), Kawai et al. note that the currently approved GLP-1 receptor agonists are peptide-based and that small-molecule activators with optimal drug properties have been hard to obtain. From a high-resolution structure of the complex with the receptor, they showed that it binds to a unique binding pocket in the upper helical bundle, surrounded by the receptor's extracellular domain, extracellular loop 2 and transmembrane helices 1, 2, 3 and 7Sourced. The authors of the paper include researchers of Chugai Pharmaceutical and Eli LillySourced
  • Approval: on 1 April 2026 Eli Lilly announced that the FDA had approved FOUNDAYO (orforglipron). The company describes orforglipron as a once-daily, small-molecule (non-peptide) oral GLP-1 receptor agonist that was discovered by Chugai Pharmaceutical and licensed in by Lilly in 2018Sourced
  • An example of discontinuation: on 14 April 2025 Pfizer announced the discontinuation of development of danuglipron, an oral small-molecule GLP-1 receptor agonist. It says the decision followed review of the totality of the information, including a possible drug-induced liver injury in one participant of a dose-optimization study (which resolved after discontinuation), and input from regulatorsSourced
ItemOral semaglutide (peptide + SNAC)orforglipron (small molecule)
Molecular weight4113.58 g/mol902.0 g/mol (calcium salt)
Absorption enhancerCo-formulated with SNACSNAC is not listed among the excipients in the label
Estimated absolute bioavailabilityAbout 0.4–2% (depends on formulation)77% (at the 0.8 mg dose)
Food and water conditionsThe label describes taking it fasting with a small amount of water and waiting at least 30 minutesThe label describes that it can be taken with or without food
Elimination half-lifeAbout 1 weekAbout 29–49 hours
Solubility in water—The calcium salt is insoluble in water and hygroscopic

All Sourced (the oral semaglutide tablet, WEGOVY and FOUNDAYO prescribing information [Refs. 2, 3, 13]). The administration conditions are quoted to show the difference in the mechanism of absorption, not as instructions for use.

Our calculation: the difference in absorption

Comparing 77% for orforglipron with about 1–2% for oral semaglutide gives about 40 to 80 times (77 ÷ 2 to 77 ÷ 1)Our calculation. With a small molecule, the "separate material" of an absorption enhancer is no longer needed, but in its place a different organic-synthesis process from that of peptides is required. It is an example in which the choice of modality is directly a choice of materials and manufacturing (commentary in this article). Because the doses differ, this ratio is not a ratio of drug-substance amounts.

12. Generics and regulatory moves / Open issues, and what is not yet settled

(1) The first generic, and the revision of guidance for generic peptides

On 23 December 2024 the FDA approved the first generic referencing VICTOZA (liraglutide injection 18 mg/3 mL) (Hikma Pharmaceuticals USA)Sourced. On 28 July 2026 it further published revised draft product-specific guidances (PSGs) for 17 peptide products. They include liraglutide, semaglutide, tirzepatide and teriparatide, and, the FDA says, give recommendations on ANDAs (Abbreviated New Drug Applications, that is, generic applications) for peptides made by recombinant, synthetic or semi-synthetic means, testing of innate immune responses, impurity thresholds, evaluation of higher-order structure and evaluation of biological activitySourced. At the same time it withdrew the May 2021 guidance "ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin", stating that it does not reflect the FDA's current scientific thinkingSourced.

A reference product made in yeast and a generic made by chemical synthesis can be treated as the same active ingredient: the difference in manufacturing method is being converted into a matter of evaluating impurities and immunogenicity (commentary in this article). The revised PSGs are still in the draft stage, and their final content is not settledNot yet confirmed.

(2) Open issues, and what could not be confirmed

  • Manufacturing conditions and yields: the conditions, yields and solvent usage of each company's solid-phase synthesis and fermentation are not stated, because they are not published in the primary sources we consulted
  • The full picture of how SNAC acts: Knudsen and Lau said in 2019 that it is not fully understoodSourced. We could not find a primary source showing how far understanding has advanced since, within the scope of this survey
  • How far oral peptides can spread: how far the same approach can be used for peptides other than semaglutide is, given that Buckley et al. describe the mechanism of absorption as compound-specificSourced, not settled as to whether it can be generalizedNot yet confirmed
  • The place of small-molecule agonists: approval began only in 2026, and how they will be used alongside peptides is not covered here (because it bears on medical judgment)
Summary of this article
  • The half-life of native GLP-1 is 1.5 to 2 minutes. It is degraded by enzymes such as DPP-4Sourced
  • Aib at position 8 makes it resistant to the enzyme, and the fatty acid at position 26 lets it hitch a ride on albumin. The half-life of semaglutide is about 1 weekSourced
  • The half-life was extended by about 5,000 to 6,700 timesOur calculation
  • The key to going oral is the absorption enhancer SNAC. Absorption takes place near the tablet surface in the stomach, and the estimated absolute bioavailability is about 1–2%Sourced
  • For the injection and the tablet under the same product name, the weekly amount of drug substance differs by about 73 timesOur calculation
  • There are two manufacturing routes: "yeast fermentation plus chemical modification" and "solid-phase synthesis". In solid-phase synthesis a 1% difference per step matters greatly over 38 stepsOur calculation

13. Glossary

Peptide drug
A drug made of a molecule in which a few to a few dozen amino acids are linked. In the United States, 40 amino acids or fewer counts as a peptide.
GLP-1
Glucagon-like peptide-1. A hormone released from the gut in response to food.
GIP
Glucose-dependent insulinotropic polypeptide. The basis of the tirzepatide sequence.
Receptor
A protein that passes a signal into the cell when a particular molecule binds. The GLP-1 receptor is a class B GPCR.
Agonist
A molecule that binds a receptor and makes it work in the same way as the natural substance.
Partial agonist
An agonist that makes the receptor work to a lesser degree than the natural substance.
DPP-4
Dipeptidyl peptidase-4. An enzyme that cuts the N-terminal side of GLP-1 and inactivates it.
Aib
Aminoisobutyric acid. A non-coded amino acid not used in natural proteins. Used to resist DPP-4.
Albumin binding
A way to prolong action by binding the drug reversibly, through a fatty acid, to albumin, the protein abundant in blood.
Fatty diacid
An aliphatic chain with a carboxylic acid at each end. C18 for semaglutide, C20 for tirzepatide.
SNAC
Salcaprozate sodium. The absorption enhancer used in oral semaglutide tablets.
Bioavailability
The fraction of the administered amount that reaches the systemic circulation.
Solid-phase peptide synthesis (SPPS)
A synthesis in which a peptide chain attached to a resin is extended one residue at a time. Purification is done by washing.
Semi-recombinant process
A manufacturing method in which the backbone is made by a microorganism and modified afterwards by chemical reactions.
Reversed-phase chromatography
A purification method that separates molecules by differences in hydrophobicity. Used to purify peptides.
ANDA / PSG
The U.S. application for approval of a generic drug / the product-specific guidance the FDA issues for each product on generic development.

14. References (primary sources)

  1. DailyMed (FDA-approved prescribing information) "OZEMPIC (semaglutide) injection" — dailymed.nlm.nih.gov
  2. DailyMed (FDA-approved prescribing information) "RYBELSUS / OZEMPIC (semaglutide) tablets" (revised January 2026) — dailymed.nlm.nih.gov
  3. DailyMed (FDA-approved prescribing information) "WEGOVY (semaglutide) injection / tablets" — dailymed.nlm.nih.gov
  4. DailyMed (FDA-approved prescribing information) "VICTOZA (liraglutide) injection" — dailymed.nlm.nih.gov
  5. DailyMed (FDA-approved prescribing information) "MOUNJARO (tirzepatide) injection" — dailymed.nlm.nih.gov
  6. European Medicines Agency (CHMP) "Mounjaro — Assessment report" EMA/791310/2022 — ema.europa.eu
  7. Knudsen, L.B., Lau, J. "The Discovery and Development of Liraglutide and Semaglutide" Frontiers in Endocrinology 10, 155 (2019). doi:10.3389/fendo.2019.00155 — pmc.ncbi.nlm.nih.gov
  8. Lau, J. et al. "Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide" Journal of Medicinal Chemistry 58(18), 7370–7380 (2015). doi:10.1021/acs.jmedchem.5b00726 — pubmed.ncbi.nlm.nih.gov
  9. Buckley, S.T. et al. "Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist" Science Translational Medicine 10(467), eaar7047 (2018). doi:10.1126/scitranslmed.aar7047 — pubmed.ncbi.nlm.nih.gov
  10. The Royal Swedish Academy of Sciences "The Nobel Prize in Chemistry 1984 — Press release" — nobelprize.org
  11. Isidro-Llobet, A. et al. "Sustainability Challenges in Peptide Synthesis and Purification: From R&D to Production" The Journal of Organic Chemistry 84(8), 4615–4628 (2019). doi:10.1021/acs.joc.8b03001 — pubmed.ncbi.nlm.nih.gov
  12. Kawai, T. et al. "Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist" PNAS 117(47), 29959–29967 (2020). doi:10.1073/pnas.2014879117 — pmc.ncbi.nlm.nih.gov
  13. DailyMed (FDA-approved prescribing information) "FOUNDAYO (orforglipron) tablets" — dailymed.nlm.nih.gov
  14. Eli Lilly and Company "FDA approves Lilly's Foundayo™ (orforglipron)…", 1 April 2026 (PR Newswire) — prnewswire.com
  15. Pfizer "Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron", 14 April 2025 — pfizer.com
  16. FDA "FDA Approves First Generic of Once-Daily GLP-1 Injection to Lower Blood Sugar in Patients with Type 2 Diabetes", 23 December 2024 — fda.gov
  17. FDA "FDA Publishes Revised Draft Product-Specific Guidances for Certain Generic Peptide Products", 28 July 2026 — fda.gov
  18. U.S. Code of Federal Regulations (eCFR) "21 CFR 600.3 Definitions" — ecfr.gov
  19. FDA "'Deemed to be a License' Provision of the BPCI Act" — fda.gov

15. Claim-to-source audit

Claim in the textBasisCategory
That semaglutide is a GLP-1 analog with 94% sequence homology to human GLP-1 that selectively binds and activates the GLP-1 receptor. That the main prolonging mechanism is albumin binding promoted by modifying lysine 26 with a hydrophilic spacer and a C18 fatty diacid, that position 8 is modified to stabilize against DPP-4 degradation, that the substitution at position 34 is so that only one fatty diacid is attached, and that the peptide backbone is made by yeast fermentation. Molecular weight 4113.58 g/mol, half-life of about 1 week, absolute bioavailability of 89% after subcutaneous administration, and the excipientsOZEMPIC (injection) prescribing information
Reference 1 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
Sourced
The excipients of the oral semaglutide tablets (RYBELSUS 3, 7, 14 mg; OZEMPIC tablets 1.5, 4, 9 mg), co-formulation with SNAC, absorption occurring mainly in the stomach, the estimated absolute bioavailability (RYBELSUS about 0.4–1%, OZEMPIC tablets about 1–2%), no clinically meaningful difference in steady-state AUC and Cmax between the two products, that they cannot be interchanged on a milligram basis, the study results in which absorption changed with the amount of water and the fasting time after dosing, taking it fasting with a small amount of water and waiting at least 30 minutes, and not splitting, crushing or chewing the tabletRYBELSUS / OZEMPIC tablets prescribing information
Reference 2 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98
Sourced
That the WEGOVY injection maintenance dose is 2.4 mg once weekly and the tablet maintenance dose is 25 mg once daily, that the tablet contains SNAC as an absorption enhancer with an estimated absolute bioavailability of about 1–2% and the injection 89%, and the reference to large variability in blood concentration for the tabletWEGOVY prescribing information
Reference 3 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
Sourced
That GLP-1(7-37) has a half-life of 1.5 to 2 minutes because of degradation by DPP-4 and NEP. That the precursor peptide of liraglutide is made by a process that includes recombinant DNA expression in baker's yeast, that lysine 34 is replaced with arginine giving 97% homology to native GLP-1, that a C16 fatty acid (palmitic acid) is attached to lysine 26 through a glutamic-acid spacer, the molecular weight of 3751.2, and the plasma half-life of 13 hours after subcutaneous administrationVICTOZA prescribing information
Reference 4 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4
Sourced
That tirzepatide is a once-weekly GIP receptor and GLP-1 receptor agonist, based on the GIP sequence, with Aib at positions 2 and 13, a C-terminal amide, and 1,20-eicosanedioic acid attached to lysine 20 through a linker. Molecular weight 4813.53 Da, half-life of about 5 daysMOUNJARO prescribing information
Reference 5 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
Sourced
That tirzepatide is a synthetic peptide of 39 amino acids, that the linker consists of γ-Glu and two 8-amino-3,6-dioxaoctanoic acid units and partly resembles polyethylene glycol, that it is made by standard solid-phase peptide synthesis (including the addition of the lysine 20 side chain) with side-chain deprotection at the same time as cleavage from the resin and purification, concentration, solvent exchange, isolation and drying by reversed-phase chromatography, and that the drug substance is made at one manufacturing siteEMA public assessment report (Mounjaro, EMA/791310/2022)
Reference 6 https://www.ema.europa.eu/en/documents/assessment-report/mounjaro-epar-public-assessment-report_en.pdf
Sourced
That the aim of fatty-acid modification is to protect against both DPP-IV degradation and renal filtration through reversible albumin binding. That in the alanine scan only Aib at position 8 combined DPP-IV stability with high receptor affinity. The approaches of albiglutide (albumin fusion) and dulaglutide (Fc fusion). That two fatty acids reduced action at the receptor. That in systematic testing from C12 to C20 the C18 fatty diacid with a γGlu-2xOEG linker gave the best balance of albumin affinity and receptor action. That fatty acids of C10 to C18 bind at seven sites on albumin. That replacing position 34 with arginine made possible a semi-recombinant process in which the backbone is made recombinantly and the fatty acid is attached afterwards. That SNAC has GRAS status for food use and that the molecular mechanism of its absorption enhancement is not fully understood (as of 2019)Knudsen and Lau (2019)
Reference 7 https://pmc.ncbi.nlm.nih.gov/articles/PMC6474072/
Sourced
That the GLP-1 receptor affinity of semaglutide (0.38 ± 0.06 nM) fell to one third of that of liraglutide and its albumin affinity roseLau et al. (2015), abstract
Reference 8 https://pubmed.ncbi.nlm.nih.gov/26308095/
Sourced
That oral administration of therapeutic peptides is hampered by the gastrointestinal barrier and enzymatic degradation. That absorption of semaglutide co-formulated with SNAC takes place in the stomach, is confined to the area next to the tablet surface and requires SNAC, that SNAC protects against enzymatic degradation by local buffering and raises absorption only temporarily, and that the mechanism is compound-specific and transcellular with no evidence of an effect on tight junctionsBuckley et al. (2018), abstract
Reference 9 https://pubmed.ncbi.nlm.nih.gov/30429357/
Sourced
That a 90% yield per step gives an overall yield of 0.003% after 100 steps, that solid-phase synthesis makes 99.5% or more per step possible and raises the overall yield to 61%, and the principle of removing by-products by washingNobel Foundation, 1984 Chemistry press release
Reference 10 https://www.nobelprize.org/prizes/chemistry/1984/press-release/
Sourced
That peptide synthesis relies mainly on older technology and uses large quantities of hazardous reagents and solvents, and that in 2016 the ACS GCI Pharmaceutical Roundtable named the development of greener processes for peptide active ingredients a critical unmet needIsidro-Llobet et al. (2019), abstract
Reference 11 https://pubmed.ncbi.nlm.nih.gov/30900880/
Sourced
That approved GLP-1 receptor agonists are peptide-based and small molecules with optimal properties were hard to obtain; that LY3502970 (OWL833) is a partial agonist biased toward G-protein activation and selective against other class B GPCRs; that it binds in a pocket of the upper helical bundle surrounded by the extracellular domain, extracellular loop 2 and transmembrane helices 1, 2, 3 and 7. That the authors include researchers of Chugai Pharmaceutical and Eli LillyKawai et al. (2020)
Reference 12 https://pmc.ncbi.nlm.nih.gov/articles/PMC7703558/
Sourced
The molecular weight of orforglipron calcium salt, 902.0 g/mol; insoluble in water and hygroscopic; absolute bioavailability of 77% at the 0.8 mg dose; that it can be taken with or without food; elimination half-life of about 29–49 hours; the list of excipientsFOUNDAYO prescribing information
Reference 13 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62
Sourced
The announcement that the FDA approved FOUNDAYO (orforglipron) on 1 April 2026; that it is a once-daily small-molecule (non-peptide) oral GLP-1 receptor agonist; that it was discovered by Chugai Pharmaceutical and licensed in by Lilly in 2018Eli Lilly announcement (a statement of fact about its own product)
Reference 14 https://www.prnewswire.com/news-releases/fda-approves-lillys-foundayo-orforglipron-the-only-glp-1-pill-for-weight-loss-that-can-be-taken-any-time-of-day-without-food-or-water-restrictions-302731485.html
Sourced
That on 14 April 2025 Pfizer announced the discontinuation of danuglipron; that one participant in a dose-optimization study had a possible drug-induced liver injury that resolved after discontinuation; that the decision took into account all the information and the input of regulatorsPfizer announcement (a statement of fact about its own development candidate)
Reference 15 https://www.pfizer.com/news/press-release/press-release-detail/pfizer-provides-update-oral-glp-1-receptor-agonist
Sourced
That on 23 December 2024 the FDA approved the first generic referencing VICTOZA (liraglutide 18 mg/3 mL) to Hikma Pharmaceuticals USAFDA press release
Reference 16 https://www.fda.gov/news-events/press-announcements/fda-approves-first-generic-once-daily-glp-1-injection-lower-blood-sugar-patients-type-2-diabetes
Sourced
That on 28 July 2026 the FDA published revised draft PSGs for 17 peptide products with recommendations on ANDAs for recombinant, synthetic and semi-synthetic peptides, innate immune response testing, impurity thresholds, higher-order structure and biological activity, and that it withdrew the May 2021 guidance on synthetic-peptide ANDAsFDA publication
Reference 17 https://www.fda.gov/drugs/drug-alerts-and-statements/fda-publishes-revised-draft-product-specific-guidances-certain-generic-peptide-products
Sourced
That a protein is defined as an alpha amino acid polymer of more than 40 amino acids21 CFR 600.3(h)(6)
Reference 18 https://www.ecfr.gov/current/title-21/chapter-I/subchapter-F/part-600/subpart-A/section-600.3
Sourced
That the FDA treats polymers of 40 or fewer amino acids as "peptides" and excludes them from the 2020 "deemed to be a license" provisionFDA page explaining the "deemed to be a license" provision
Reference 19 https://www.fda.gov/drugs/guidance-compliance-regulatory-information/deemed-be-license-provision-bpci-act
Sourced
The half-life ratios (liraglutide about 390–520 times, tirzepatide about 3,600–4,800 times, semaglutide about 5,000–6,700 times) and the log conversion. About 36% less drug substance from the ratio of RYBELSUS 14 mg to OZEMPIC tablets 9 mg. The weekly drug-substance amounts for WEGOVY (injection 2.4 mg, tablet 175 mg, about 73 times) and the absorbed amounts (about 2.1 mg, about 1.8–3.5 mg). The cumulative shares over 38 couplings (about 96%, 83%, 68%, 46% and 1.8%) and that about 32% of chains have a missing coupling at 99% per step. The ratio of the bioavailability of orforglipron to that of oral semaglutide (about 40–80 times)Our calculation. Simple conversions of the values in the labels (doses, half-lives, bioavailability); the measurement conditions and individual variation are not matched. The per-step coupling rates are assumptions made by this article and are not actual manufacturing conditions or yields. None of these shows therapeutic equivalence or the merit of any drugOur calculation
The final content of the revised PSGs. How far the oral approach can be generalized to peptides other than semaglutideThe PSGs are at the draft stage, and on generalization we could not confirm, at the time of this article's survey (September 2026), any primary information beyond the paper's statement that the mechanism is compound-specific (commentary in this article)Not yet confirmed
The conditions, yields and solvent usage of each company's solid-phase synthesis and fermentation. The step at which Aib at position 8 of semaglutide is introduced. Whether the difference in content of the OZEMPIC tablets arose from the formulation change alone. How far understanding of SNAC's action has advanced since. The SNAC content per tabletCould not be confirmed in the primary sources consulted, so they are not statedCommentary
The arrangement of the three weaknesses of peptides (degradation, renal clearance, absorption) as solved by chemical and materials design. Likening the fatty acid and the PEG-like linker to the design of a surfactant or coupling agent, likening the idea of removing a reactive site from the sequence to surface treatment, and reading albumin binding as the design of an adsorption/desorption balance; the reading that the design chose "staying long" over "acting strongly". That going oral is also a decision that raises the amount of drug substance, and that the disintegration and dissolution of the tablet govern absorption. Likening the impurities of solid-phase synthesis to defects in sequential polymerization, and the reading that going oral increases the use of solvents and resin. The reading that the difference in manufacturing method is being converted into evaluation of impurities and immunogenicityThis article's arrangement and commentary based on published content. Not views stated by the authors of the papers, regulators or companiesCommentary
The efficacy (weight loss, blood-glucose improvement and so on) and safety of each product, comparisons between products, and how they are used alongside each otherThis article explains materials and manufacturing technology and does not evaluate or compare therapeutic effect or safety. Doses and administration conditions are quoted to explain the amount of drug substance and the mechanism of absorption, not as instructions for useCommentary
That the figures combine ImageGen-generated explanatory images and vector drawings, kept distinct from real objects and measured imagesNote by this articleCommentary

Last updated 26 September 2026. Sources are limited to primary material (FDA-approved prescribing information [DailyMed], EMA public assessment reports, FDA publications, the U.S. Code of Federal Regulations, Nobel Foundation announcements, official company announcements and peer-reviewed papers). Because the article includes readings on molecular design, formulation and process, those are marked as commentary and kept separate from sourced fact. Each company's manufacturing conditions, yields and solvent usage, the SNAC content, the step at which Aib is introduced in semaglutide, and the final content of the revised PSGs could not be confirmed in published primary sources and are not stated here. This article is an explanation of materials and manufacturing technology, and it does not evaluate or compare efficacy or safety and is not medical advice. All figures are explanatory concept diagrams. The figures combine ImageGen-generated explanatory images and vector drawings. The generated images are not photographs, micrographs or measured data of real objects. The original schematics, which include numbers and sources, are either shown as they are or kept expandable under the new images.

🌐 Japanese